Background/Aims Inflammatory bowel disease (IBD) is increasing across the globe, more so in populous countries like India. We aimed to study the disease burden and epidemiological trends of IBD in India and look closer into the disease pattern across the country from 1990 to 2019.
Methods The burden of IBD was estimated in India using the data from the Global Burden of Disease estimate for 2019, which is a comprehensive worldwide project. The analysis included various parameters like incidence, prevalence, mortality, disability-adjusted life years, years lived with disability, and years of life lost as age-adjusted rates (per 100,000 population). Using modeling, the prediction was also made for 2050 in India.
Results The age-standardized incidence, prevalence, mortality, and disability rates of IBD in India for 2019 were 2.34, 20.34, 0.40, and 13.04, respectively. These are lower than the global incidence, prevalence, mortality, and disability rates of 4.97, 59.25, 0.54, and 20.15, respectively. The annual rates of change in incidence, prevalence, mortality, and disability rates in India from 1990 to 2019 were 0.05, –0.02, –0.36, and –0.35, respectively. The annual rates of change in incidence and prevalence are higher than the global rate of –0.18 and –0.19, while the annual rates of change in mortality and disability are lower than the global rate of –0.19 and –0.26.
Conclusions The incidence and prevalence of IBD in India are lower compared to the global population but are increasing at a faster rate than the global population.
Citations
Citations to this article as recorded by
Efficacy of tirzepatide for weight loss and it’s comparative effectiveness to weight loss surgery in inflammatory bowel disease Aakash Desai, Himsikhar Khataniar, Fjona Tabaku, Jana G. Hashash, Francis A. Farraye, Gursimran S. Kochhar Indian Journal of Gastroenterology.2026; 45(3): 564. CrossRef
Relation of ultra-processed food consumption with ulcerative colitis disease activity Nancy Sahni, Ayushi, Urvashi Rana, Radhika Khosla, Usha Dutta, Rakesh Kochhar, Vishal Sharma Indian Journal of Gastroenterology.2026; 45(3): 607. CrossRef
Impact of GLP-1 analogues on immune-mediated inflammatory diseases: A systematic review Chhagan L. Birda, Fadwa Ibrahim, Abhirup Chatterjee, Anuraag Jena, Vishal Sharma, Shaji Sebastian Autoimmunity Reviews.2026; 25(1): 103936. CrossRef
Burden of anemia in inflammatory bowel disease: A systematic review and meta-analysis Rupa Tharu, Savitesh Kushwaha, Rachana Srivastava, Vaneet Jearth, Nitin Kaushal, Anupam Kumar Singh, Shweta Khandelwal, Poonam Khanna Clinical Epidemiology and Global Health.2026; 37: 102262. CrossRef
Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply Suprabhat Giri, Anuraag Jena, Vishal Sharma, Shaji Sebastian Alimentary Pharmacology & Therapeutics.2026; 63(6): 901. CrossRef
Histological interpretation and reporting of intestinal mucosal biopsies in suspected cases of inflammatory bowel disease: Joint IAPM-ISG-CCFI Working Group Recommendations Prasenjit Das, Puja Sakhuja, Aminder Singh, Arshdeep Singh, Sagir Akhtar, Saurabh Kedia, Vishal Sharma, Kim Vaiphei, Anna Pulimood, Roopa Rachel Paulose, Anuradha Sekaran, Sanjeev Vasudev Katti, Mala Banerjee, Ritambhra Nada, Nuzhat Hussain, Niraj Kumari, Indian Journal of Gastroenterology.2026; 45(3): 364. CrossRef
Stricturing Phenotype Predisposes to Small Bowel and Colorectal Malignancy in Crohn's Disease Kiran Josy Kanjamala, Prakash Zacharias, Shibi Mathew, Hasim Ahamed, Remya R. Pai, Anvin Kurian Thomas, Arjun R. Gupta, Mathew Philip JGH Open.2026;[Epub] CrossRef
Comparative efficacy of advanced therapies in biological-exposed ulcerative colitis – a network meta-analysis of randomized trials Suprabhat Giri, Akshay Kulkarni, Sidharth Harindranath, Sayan Malakar, Anuraag Jena, Harshad Joshi, Preetam Nath European Journal of Gastroenterology & Hepatology.2026;[Epub] CrossRef
Modulation of colonic DNA methyltransferase by mild moxibustion and electroacupuncture in ulcerative colitis TET2 knockout mice Gege Feng, Yue Zhang, Huangan Wu, Lu Zhu, Hongxiao Xu, Zhe Ma, Yan Huang Digital Chinese Medicine.2025; 8(1): 100. CrossRef
Research Status of Anemia Associated with Inflammatory Bowel Disease 莉娟 孙 Journal of Clinical Personalized Medicine.2025; 04(03): 712. CrossRef
The adoption of a westernized gut microbiome in Indian Immigrants and Indo-Canadians is associated with dietary acculturation Leah D. D’Aloisio, Mamatha Ballal, Sanjoy Ghosh, Natasha Haskey, Nijiati Abulizi, Ramin Karimianghadim, Chuyi Liu, Pacha Sruthi, Lakshmipriya Nagarajan, Sudha Vasudevan, Vignesh Shetty, Mrudgandha Purandare, Ushasi Bhaumik, Debaki Ranjan Howlader, Sepideh npj Biofilms and Microbiomes.2025;[Epub] CrossRef
Next-generation non-animal models for inflammatory bowel disease: In vitro and in silico approaches for mechanistic understanding Priyanka Raju Chougule, Sukesh Narayan Sinha NAM Journal.2025; 1: 100051. CrossRef
Modulation of inflammatory and cuproptotic crosstalk by Ethyl and propyl gallate: a multi-targeted strategy against experimental colitis Priyanka Raju Chougule, Sukesh Narayan Sinha, Sudip Ghosh, Sangaraju Rajendra, Saikanth Varma, Suresh Challa, Manjula Bhanoori Molecular Biology Reports.2025;[Epub] CrossRef
Stroke in paediatric Crohn’s disease Sai Anjali Kambala, Seema Pavaman Sindgikar, Daniya Hameed, Chandrashekar J Sorake BMJ Case Reports.2025; 18(12): e269145. CrossRef
Background/Aims Coronavirus disease 2019 (COVID-19) is recognized to have variable clinical manifestations. The clinical presentation of patients with inflammatory bowel disease (IBD) having COVID-19 is unclear.
Methods We identified articles reporting about the clinical presentation of COVID-19 in those with underlying IBD from PubMed and Embase. The studies, irrespective of design or language, were included. The overall pooled frequency of various symptoms was estimated. Joanna Briggs Institute Critical appraisal checklist was used to assess the quality of studies.
Results Eleven studies, including 1,325 patients, were included in the pooled analysis. The pooled estimates for clinical presentation were; fever: 67.53% (95% confidence interval [CI], 45.38–83.88), cough: 59.58% (95% CI, 45.01–72.63), diarrhea: 27.26% (95% CI, 19.51–36.69), running nose: 27% (95% CI, 15.26–43.19) and dyspnea: 25.29% (95% CI, 18.52–33.52). The pooled prevalence rates for abdominal pain, nausea and vomiting were 13.08% (95% CI, 9.24–18.19), 10.08% (95% CI, 5.84–16.85) and 8.80% (95% CI, 4.43–16.70) per 100 population, respectively.
Conclusions The clinical presentation of COVID-19 in IBD patients is similar to the general population.
Citations
Citations to this article as recorded by
Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease Amin Alirezaylavasani, Ingrid Marie Egner, Børresdatter Dahl, Adity Chopra, Taissa de Matos Kasahara, Guro Løvik Goll, Jørgen Jahnsen, Gunnveig Grødeland, John Torgils Vaage, Fridtjof Lund-Johansen, Jan Cato Holter, Bente Halvorsen, Kristin Kaasen Jørgens Clinical Immunology.2025; 271: 110404. CrossRef
Small Bowel Diverticulosis and COVID-19: Awareness Is the Key: A Case Series and Review of the Literature Petros Bangeas, Nikolaos Konstantinidis, Tania Chrisopoulou, Despoina Karatzia, Alexandros Giakoustidis, Vasileios Papadopoulos Medicina.2024; 60(2): 229. CrossRef
Exacerbated gastrointestinal symptoms and long COVID in IBD patients with SARS-CoV-2 infection: A multi-center study from taiwan Tsung-Yu Tsai, Jia-Feng Wu, Meng-Tzu Weng, Chiao-Hsiung Chuang, Tien-Yu Huang, Wei-Chen Tai, Chi-Ming Tai, Chen-Shuan Chung, Chih-Cheng Chen, Ching-Pin Lin, Yuan-Yao Tsai, Shu-Chen Wei Journal of the Formosan Medical Association.2024; 123(8): 866. CrossRef
COVID-19 IN INFLAMMATORY BOWEL DISEASE: SHOULD WE BE MORE CAREFUL WITH THE USE OF SALICYLATES? Mariana Rolim Fernandes MACEDO, Carlos Arthur Fernandes SOBREIRA, Carola Braz de LAVOR, Camila Ribeiro RÔLA, Ticiana Maria de Lavor ROLIM, Francisco Sérgio Rangel de Paula PESSOA, Milena Santana GIRÃO, Caio César Furtado FREIRE, Ranna Caroline Bezerra SIE Arquivos de Gastroenterologia.2024;[Epub] CrossRef
Impact of preexisting digestive problems on the gastrointestinal symptoms of patients with omicron variant of SARS-CoV-2 infection Xinghuang Liu, Bayasgalan Luvsandagva, Dongke Wang, Siran Zhu, Zhiyue Xu, Dan Zhou, Xiaotian Xie, Wei Qian, Xiaohua Hou, Tao Bai, Dong Keon Yon PLOS ONE.2024; 19(10): e0312545. CrossRef
Diarrhea and Coronavirus Disease 2019 Infection David M. Friedel, Mitchell S. Cappell Gastroenterology Clinics of North America.2023; 52(1): 59. CrossRef
Managing IBD in the COVID-19 era Nicholas Scalzo, Ryan C. Ungaro Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients Alfredo Papa, Marcello Covino, Sara Sofia De Lucia, Angelo Del Gaudio, Marcello Fiorani, Giorgia Polito, Carlo Romano Settanni, Andrea Piccioni, Francesco Franceschi, Antonio Gasbarrini World Journal of Gastroenterology.2023; 29(26): 4099. CrossRef
Twelve Months with COVID-19: What Gastroenterologists Need to Know Giulia Concas, Michele Barone, Ruggiero Francavilla, Fernanda Cristofori, Vanessa Nadia Dargenio, Rossella Giorgio, Costantino Dargenio, Vassilios Fanos, Maria Antonietta Marcialis Digestive Diseases and Sciences.2022; 67(7): 2771. CrossRef
Perceptions and Behaviors of Patients with Inflammatory Bowel Disease during the COVID-19 Crisis Yoo Jin Lee, Kyeong Ok Kim, Min Cheol Kim, Kwang Bum Cho, Kyung Sik Park, Byeong Ik Jang Gut and Liver.2022; 16(1): 81. CrossRef
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic Simeng Lin, Louis HS Lau, Neil Chanchlani, Nicholas A Kennedy, Siew C Ng Gut.2022; 71(7): 1426. CrossRef
Vaccination strategies for Korean patients with inflammatory bowel disease Yoo Jin Lee, Eun Soo Kim The Korean Journal of Internal Medicine.2022; 37(5): 920. CrossRef
Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung Intestinal Research.2022; 20(4): 431. CrossRef
Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis Ho Min Yong, Sung-Jo Park, Seong Ran Jeon, Heesu Park, Hyun Gun Kim, Tae Hee Lee, Junseok Park, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Hyeon Jeong Goong, Suyeon Park Medicine.2021; 100(34): e27065. CrossRef
KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung The Korean Journal of Gastroenterology.2021; 78(2): 105. CrossRef
The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD Giorgos Bamias, Georgios Kokkotis, Angeliki Christidou, Dimitrios K. Christodoulou, Vasileios Delis, Georgia Diamantopoulou, Smaragdi Fessatou, Anthia Gatopoulou, Olga Giouleme, Panagiota Kafritsa, Chrisostomos Kalantzis, Andreas Kapsoritakis, Pantelis Ka European Journal of Gastroenterology & Hepatology.2021; 33(1S): e810. CrossRef